OPRX - OptimizeRx Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
12.10
+0.15 (+1.26%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.95
Open11.89
Bid11.86 x 1100
Ask12.27 x 1800
Day's Range11.86 - 12.51
52 Week Range4.83 - 18.39
Volume11,925
Avg. Volume39,324
Market Cap146.351M
Beta (3Y Monthly)1.13
PE Ratio (TTM)605.00
EPS (TTM)0.02
Earnings DateMay 11, 2017 - May 12, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.92
Trade prices are not sourced from all markets
  • Should You Worry About OptimizeRx Corporation's (NASDAQ:OPRX) CEO Salary Level?
    Simply Wall St.3 days ago

    Should You Worry About OptimizeRx Corporation's (NASDAQ:OPRX) CEO Salary Level?

    Will Febbo has been the CEO of OptimizeRx Corporation (NASDAQ:OPRX) since 2016. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll consider gro...

  • GlobeNewswire10 days ago

    OptimizeRx Expands Investment in Hospitals and Health Systems with Latest Tech and Personnel Adds

    OptimizeRx Corp. (OPRX), a leading digital health messaging platform for the pharmaceutical industry, announced its latest platform integration with the health care industry’s leading acute electronic health record (EHR) systems, including Epic and Cerner. This latest announcement is a reflection of the company’s continued investment in hospitals and health systems, also emphasized in the latest company hiring of Denys Ashby as vice president of Hospitals & Health Systems.

  • GlobeNewswire29 days ago

    OptimizeRx Survey Shows Providers Want to Engage with Patients on Drug Costs for Adherence and Improved Care

    OptimizeRx Corp. (OPRX), a leading digital health messaging platform for the pharmaceutical industry , released its full results and findings from its Drug Cost Survey. The cost of prescription drugs is on the mind of physicians and patients alike.

  • GuruFocus.comlast month

    OptimizeRx Corp (OPRX) Files 10-K for the Fiscal Year Ended on December 31, 2018

    OptimizeRx Corp is a technology solutions company serving the healthcare industry. OptimizeRx Corp had annual average EBITDA growth of 23.90% over the past ten years. Warning! GuruFocus has detected 2 Warning Signs with OPRX.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of OPRX earnings conference call or presentation 26-Feb-19 9:30pm GMT

    Q4 2018 OPTIMIZERx Corp Earnings Call

  • GlobeNewswirelast month

    OptimizeRx to Present at the 31st Annual ROTH Conference on March 17-19, 2019; Pre-Conference Webcast Available March 11

    OptimizeRx Corp. (OPRX), a leading digital health messaging platform for the pharmaceutical industry, has been invited to present at the 31st Annual ROTH Conference being held at The Ritz Carlton, Laguna Niguel in Orange County, California, on March 17-19, 2019. Last year, the ROTH Conference hosted close to 550 participating companies and more than 4,700 attendees, including institutional investors, analysts, family offices and high net worth investors. The network has become the largest of its kind, now reaching more than half of the ambulatory patient market in the U.S.

  • GlobeNewswire2 months ago

    OptimizeRx Reports Fourth Quarter 2018 Results; Net Revenue Up 64% to a Record $6.6 Million, Driving First Profitable Year

    ROCHESTER, Mich., Feb. 26, 2019 -- OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital health messaging for the pharmaceutical industry, reported results for the.

  • Should We Be Cautious About OptimizeRx Corporation’s (NASDAQ:OPRX) ROE Of 0.6%?
    Simply Wall St.2 months ago

    Should We Be Cautious About OptimizeRx Corporation’s (NASDAQ:OPRX) ROE Of 0.6%?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! While some investors are already well versed in financial metricsRead More...

  • GlobeNewswire2 months ago

    OptimizeRx Sets Fourth Quarter and Full Year 2018 Conference Call for Tuesday, February 26, 2018 at 4:30 p.m. ET

    ROCHESTER, Mich., Feb. 13, 2019 -- OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital health messaging for the pharmaceutical industry, will hold a conference call.

  • GlobeNewswire2 months ago

    OptimizeRx Survey Shows Providers Believe They Have a Role in Discussing Care Costs with Patients

    OptimizeRx Corp. (OPRX), a leading provider of digital health messaging for the pharmaceutical industry, announced today its initial findings from a physician survey focused on prescription drug costs.

  • GlobeNewswire2 months ago

    OptimizeRx Introduces OptimizeMDs, a “Voice of the Physician” Multi-Specialty Digital Health Panel

    OptimizeRx Corp. (OPRX), a leading provider of digital health messaging for the pharmaceutical industry, has formed OptimizeMDs, a multi-specialty physician panel with the mission of improving the effectiveness of digital health communications delivered throughout the care continuum. “OptimizeRx provides technology designed to streamline and improve communications between pharma/life sciences, providers and patients,” said Miriam Paramore, president of OptimizeRx.

  • OptimizeRx partners with IllumiCare
    American City Business Journals2 months ago

    OptimizeRx partners with IllumiCare

    OptimizeRx Corp., a digital health messaging company, for the pharmaceutical industry, has formed a partnership with Birmingham's IllumiCare.  IllumiCare’s Smart Ribbon platform will feature a new app from OptimizeRx that presents drug-savings opportunities that health providers and the clinical care team can distribute to the patient directly at the point-of-care. “Our collaboration with OptimizeRx will enable providers to be better stewards of health care spending,” said G.T. LaBorde, CEO of IllumiCare. “Our Smart Ribbon technology, accessible within the provider’s workflow in the electronic health record (EHR), will give providers easy access to render coupons, savings opportunities or alternate drug choices to best support the patient.” IllumiCare offers a non-intrusive electronic medical record tool that provides clinicians with patient-specific information ranging from real-time costs of procedures to predicted patient harm data.

  • GlobeNewswire3 months ago

    OptimizeRx Announces New Partnership with Health IT Pioneer lllumiCare

    OptimizeRx Corp. (OPRX), a leading provider of digital health messaging for the pharmaceutical industry, announced a new partnership with IllumiCare, a pioneer in point-of-care healthcare information technology that saves hospitals millions annually. IllumiCare's Smart Ribbon® platform will feature a new app from OptimizeRx, the RxSavings App, to present drug savings opportunities—such as co-pay offers and vouchers—that providers and the clinical care team can distribute to the patient directly at the point-of-care.

  • Does Market Volatility Impact OptimizeRx Corporation’s (NASDAQ:OPRX) Share Price?
    Simply Wall St.3 months ago

    Does Market Volatility Impact OptimizeRx Corporation’s (NASDAQ:OPRX) Share Price?

    If you own shares in OptimizeRx Corporation (NASDAQ:OPRX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of Read More...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of OPRX earnings conference call or presentation 5-Nov-18 9:30pm GMT

    Q3 2018 OPTIMIZERx Corp Earnings Call

  • GlobeNewswire4 months ago

    OptimizeRx Announces Pricing of Public Offering of Common Stock

    OptimizeRx Corporation (OPRX), a leading provider of digital health messaging for the pharmaceutical industry, today announced the pricing of the previously announced underwritten public offering by WPP Luxembourg Gamma Three S.à r.l., a shareholder of OptimizeRx, of 2,103,702 shares of OptimizeRx common stock, at a public offering price of $10.00 per share.  In connection with the offering, OptimizeRx granted the underwriters a 30-day option to purchase up to an additional 315,555 newly issued shares of common stock from the Company at the public offering price less the underwriting discount and commissions. The offering is expected to close on or about December 20, 2018, subject to customary closing conditions.

  • GlobeNewswire4 months ago

    OptimizeRx Announces Proposed Public Offering of Common Stock

    OptimizeRx Corporation (OPRX), a leading provider of digital health messaging for the pharmaceutical industry, today announced a proposed underwritten public offering by WPP Luxembourg Gamma Three S.à r.l., a shareholder of OptimizeRx, of 2,103,702 shares of OptimizeRx common stock. In connection with this offering, OptimizeRx expects to grant the underwriters a 30-day option to purchase up to an additional 315,555 newly issued shares of common stock from the Company at the public offering price less the underwriting discount and commissions.

  • GlobeNewswire5 months ago

    OptimizeRx Joins MSCI USA Microcap Index

    OptimizeRx Corp. (OPRX), a leading provider of digital health messaging for the pharmaceutical industry, joined the MSCI USA Microcap Index at the conclusion of the MSCI indexes semi-annual reconstitution, effective after the U.S. market closes today, according to the MSCI website. “Joining the MSCI USA Microcap Index represents another major market milestone for OptimizeRx after our up-listing to Nasdaq earlier this year,” said OptimizeRx CEO, William Febbo.

  • ACCESSWIRE5 months ago

    OptimizeRx to Present at 11th Annual LD Micro Main Event on December 4-6, 2018

    ROCHESTER, MI / ACCESSWIRE / November 28, 2018 / OptimizeRx Corp. (OPRX), a leading provider of digital health messaging for the pharmaceutical industry, has been invited to present at 11th Annual LD Micro Main Event institutional investor conference being held on December 4-6, 2018 at the Luxe Sunset Bel Air Hotel in Bel Air, California. William Febbo, CEO of OptimizeRx, is scheduled to present on Tuesday, December 4, at 1:30 p.m. Pacific time, with one-on-one meetings with institutional analysts and investors. The presentation will be also webcast live and available for replay here and via the investor relations section of the company's website at www.optimizerx.com.

  • Do Institutions Own OptimizeRx Corporation (NASDAQ:OPRX) Shares?
    Simply Wall St.5 months ago

    Do Institutions Own OptimizeRx Corporation (NASDAQ:OPRX) Shares?

    The big shareholder groups in OptimizeRx Corporation (NASDAQ:OPRX) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership Read More...

  • GlobeNewswire5 months ago

    Recent Analysis Shows Construction Partners, OptimizeRx, OncoMed Pharmaceuticals, Issuer Direct, Red Violet, and Golden Minerals Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire5 months ago

    OptimizeRx to Ring Nasdaq Closing Bell on Friday, November 16

    OptimizeRx Corp. (OPRX), a leading provider of digital health messaging for the pharmaceutical industry, has been invited to ring the Nasdaq Stock Market Closing Bell on Friday, November 16, to commemorate the company’s recent market uplisting. In honor of the occasion, William Febbo, CEO of OptimizeRx, will ring the closing bell at the Nasdaq Market site in Times Square, where he will be joined by other members of the OptimizeRx team.

  • GlobeNewswire5 months ago

    OptimizeRx Reports Third Quarter 2018 Results; Net Revenue Up 75% to a Record $5.4 Million, Driving $0.02 EPS

    ROCHESTER, Mich., Nov. 05, 2018 -- OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital health messaging for the pharmaceutical industry, reported results for the.

  • OptimizeRx (OPRX) Q3 Earnings Preview: What to Look Out For
    Zacks6 months ago

    OptimizeRx (OPRX) Q3 Earnings Preview: What to Look Out For

    OptimizeRx (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.